clinical trial · NCT05051891
A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma
Beijing InnoCare Pharma Tech Co., Ltd.·phase3·completed·n = 3
Treatment-naїve Mantle Cell LymphomaOrelabrutinib and R-CHOPR-CHOP
brief summary
To evaluate the efficacy of orelabrutinib combined with R-CHOP vs. R-CHOP alone in the treatment of treatment-naїve mantle cell lymphoma.
started
Dec 22, 2021
primary completion
Jun 30, 2025
completion
Jun 30, 2025
last updated
Mar 31, 2026
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol